Autoimmune Disease Therapeutics Market Research Report Up to 2031
Visiongain has published a new report on Autoimmune Disease Therapeutics Market Report to 2031. According to the Visiongain analysis, the global Autoimmune Disease Therapeutics market is anticipated to grow at a CAGR of XX% during the forecast period (2021-2031). The global Autoimmune Disease Therapeutics market is segmented By Indication (Rheumatic Disease, Multiple Sclerosis, Diabetes, Inflammatory Bowel Disease, Other) By Drug Class (Immunosuppressant drugs, Nonsteroidal anti-inflammatory drugs (NSAIDs), Biologics, Corticosteroids, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacies, Other). Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report includes detailed Profiles of Leading Autoimmune Disease Therapeutics Companies. PLUS COVID-19 Recovery Scenarios.
Download a Sample Report with Table of Contents and Figures by clicking here: @ https://www.visiongain.com/report/autoimmune-disease-therapeutics-market/
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. The surge in adoption of autoimmune disease therapeutics and rising prevalence of autoimmune disease are some of the factors driving the growth of Autoimmune Disease Therapeutics market.
COVID-19 Impact on the Global Autoimmune Disease Therapeutics Market
The Coronavirus disease (COVID-19) is new virulent disease, growing transmission and fatal outcome in the global population. The pandemic is conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), and are at high infectious risk as compared to the general population, due to overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect developed by corticosteroids and immunosuppressive drugs. However, increasing awareness about the pathophysiology of SARS-CoV-2 infection, leads to contribute towards some anti-rheumatic drugs as potential option to treat & manage COVID-19.
How the Autoimmune Disease Therapeutics Market report helps you
In summary, our 320+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Autoimmune Disease Therapeutics Market, with forecasts for by indication, by drug class, and distribution channel each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the Autoimmune Disease Therapeutics market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, Rest of Asia Pacific, Latin America and Middle East and Africa among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for Autoimmune Disease Therapeutics of the major companies involved in the Autoimmune Disease Therapeutics Market. Some of the company’s profiled in this report include-
• ABBOTT Laboratories
• Hoffmann-La Roche AG
• Johnson and Johnson
• Bio-Rad Laboratories, Inc.
• Pfizer, Inc
• Bristol-Myers Squibb
• GlaxoSmithKline PLC
• Biogen Inc
• Bayer AG
• Merck & Co., Inc.
• AbbVie, Inc.
• Chugai Pharmaceutical Co. Ltd.
• Amgen, Inc.
Surge in adoption of autoimmune disease therapeutics
The Hydroxychloroquine (antimalarial drug) is used in lupus and rheumatoid arthritis & may be helpful in some patients with Sjögren’s syndrome, enables to reduce the joint pain. The disease-modifying antirheumatic drugs (DMARDS) includes compounds such as sulfasalazine, indicated to use for Rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other auto-inflammatory conditions. The increasing adoption of various drugs corticosteroids such as prednisone or immunosuppressive agents like methotrexate (Rheumatrex), azathioprine (Imuran), mycophenolate (Cellcept) or cyclophosphamide (Cytoxan) are increasing g to treat diseases. Additionally, the researchers are evaluating rituximab (Rituxan) and other biological therapies to treat cases of Sjögren’s syndrome.
To request a overview of this report please contacts Sara Peerun at firstname.lastname@example.org or refer to our website:@ https://www.visiongain.com/report/autoimmune-disease-therapeutics-market/
Increase in incidence of autoimmune disease
According to American College of Rheumatology, it is estimated in US about 50 million people of all ages and genders have arthritis or other rheumatic conditions. The rheumatoid arthritis (RA) is common type of autoimmune arthritis, caused due to improper functioning of immune system. The patient with Sjögren’s syndrome is healthy, however, associated with rare complications such as risk for cancer of the lymph glands (lymphoma).
Increasing presence of pipeline drug
The Corbus Pharma investigational drug lenabasum, significantly completed primary objective of a Phase 2 study, without any unfavorable outcomes associated with the drug. The lenabasum is oral synthetic endocannabinoid-mimetic, used in patients with diffuse cutaneous systemic sclerosis. However, the drug does not receive US Food and Drug Administration-approval to treat overall disease. The pipeline drug for autoimmune disorder is currently in development by manufacturers, offers opportunity for promising advanced drugs.
Request your free report overview by emailing: email@example.com
Significant advancement in therapeutics
The formation of the National Organization for Rare Diseases, the Orphan Drug Act, investment for orphan drug development, the formation of the National Institutes of Health Office of Rare Diseases, and the passage of orphan drug legislation by other countries enhance the market growth. The Division of Advanced Therapeutics program is the flagship clinical research program in arthritis and autoimmune disorders at the Rebecca MacDonald Centre for Arthritis & Autoimmune Disease. It enables to develop advance therapies for rheumatic diseases, osteoarthritis, and psoriatic arthritis. However, the advancement in therapeutics enables to improvise and manage autoimmune diseases and provided availability of various option to treat the diseases.
With Information found nowhere else
our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Find more research reports on pharmaceutical drugs markets, by Visiongain:
- Top 50 Ophthalmic Drug Manufacturers Market Report
- Acromegaly Treatment Market Report
- Acetaminophen (Paracetamol) Market Report
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:
Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.
Tel: + 44 207 549 9987
USA Tel: 00 1 718 682 4567
EU Tel: 00 353 1 695 0006
Follow Us: LinkedIn | Twitter
SOURCE Visiongain Limited.